3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Everolimus
15
surufatinib
7
lutetium Lu 177 dotatate
6
lanreotide
6
amino-acid, glucose, and electrolyte solution
5
Octreotide
5
Sunitinib
4
Data Collection
4
pasireotide
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
tislelizumab
2
pembrolizumab
2
fosbretabulin
2
arginyllysine
2
Temozolomide
2
Paclitaxel
2
PM 01183
2
Irinotecan
2
Carboplatin
2
64Cu-SARTATE
2
3-Iodobenzylguanidine
2
toripalimab
1
telotristat ethyl
1
taxane
1
repotrectinib
1
pralsetinib
1
pelcitoclax
1
liposomal doxorubicin
1
gadoteridol
1
gadoterate meglumine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neuroendocrine Tumors
×
gadoterate meglumine
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled